Loading
A phase 2 trial of KRT-232 and Ruxolitinib in myeloproliferative neoplasms, run by Kartos Therapeutics, Inc., active and no longer recruiting.
KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera is a phase 2 interventional study registered as NCT03669965 by Kartos Therapeutics, Inc., with 20 participants enrolled, started 2019-01-15 and due to reach its primary completion in 2022-04. Interventions recorded: KRT-232 and Ruxolitinib.
Shares Ruxolitinib, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors and the tag pipeline.
Shares Ruxolitinib, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Ruxolitinib and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Ruxolitinib and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.